Meeting
2022 ASCO Annual Meeting
Epidemiology and clinical impact of EGFR mutation in patients with lung cancer after radical surgical treatment.
Authors
Maciej Bryl
E.J. Zeyland Wielkopolska Center of Pulmonology and Thoracic Surgery, Poznan, Poland
Maciej Bryl , Magdalena Sielewicz , Bartłomiej Budny , Aldona Woźniak , Piotr Gabryel , Mariusz Kasprzyk , Aleksander Barinow-Wojewodzki , Cezary Piwkowski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8552)
DOI
10.1200/JCO.2022.40.16_suppl.8552
Abstract #
8552
Poster Bd #
179
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L).
First Author: Hirohito Tada
Poster
2023 ASCO Annual Meeting
Differential expression analysis of circRUNX1 in patients with early resected EGFR-mutant NSCLC.
First Author: Carlos Pedraz
Poster
2021 ASCO Annual Meeting
Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).
First Author: Chao Lyu
Poster
2021 ASCO Annual Meeting
Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer.
First Author: Collin M. Blakely